Custom Antagonistic Antibody Development Service

Antagonists stem from Latin antagonista and Greek antagonistes, which means competitor, rival or opponent. In medicine, an antagonistic antibody works against the drug and blocks the immune response, whereas an agonistic antibody binds to a receptor site and induces a cascade response. As a leading service provider in antibody development, Creative Biolabs has defined numerous ligands that act as antagonists for many receptors and provides one package services covering from antigen design, peptide synthesis, to antibody production projects. In particular, we’re skilled at the development of customized antagonistic antibodies against many different targets to treat severe diseases even malignant tumors.

Overviews

Immunity responses are under the control of extracellular molecules, which exert functions in receptors present on the cell surface of the immune system and thereby are amenable to be functionally regulated by monoclonal antibodies (mAbs). Some of these mechanistic bases are activating and decide whether the response continues, while others play the role of powerful repressors. It is known that the antagonist is a key player in the human body and in clinical practices and performs on such repressors leading to enhanced immune responses. Receptor antagonists are inhibitors of receptor activity. They mimic ligands that are coupled to a receptor and prevent receptor activation by a natural ligand. And though antagonists help in binding, they would not alter the activity of receptors.

Custom Antibody Development Services at Creative Biolabs

A series of therapeutic agents based on antagonistic antibodies are under pharmacological development. One of them directed at the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitory receptor, namely ipilimumab, has been approved for the treatment with metastatic melanoma. The list of antagonist agents acting on repressors is currently being developed, which includes anti-PD-1, anti-PD-L1 (B7-H1), anti-CTLA-4, anti-KIR, and anti-TGF-β. A promising preclinical pipeline suggests that many other active targets are also being tested in patients in the near future. All of these antibodies have been studied as conventional monoclonal immunoglobulins, but other engineered antibody formats are undergoing preclinical scrutiny.

Schematic representation of the concept of immunostimulatory mAbs. Fig.1 Schematic representation of the concept of immunostimulatory mAbs. (Melero, 2013)

The generation and maintenance of immune responses are controlled by both co-inhibitory and co-stimulatory signaling through T cell receptors, many of which belong to the tumor necrosis factor (TNF) receptor superfamily or the immunoglobulin-like superfamily. Antagonistic mAbs targeting these co-receptors have the potential to improve the immunity of human bodies. Combining our rich experience in molecular biology and genetic engineering technology, Creative Biolabs has launched a broad range of antibody expression systems and provides high-quality antagonist antibody development services to support a variety of applications in clinical drug research. Furthermore, we’d like to introduce the following two kinds of custom development services for global clients.

Advantages

Make it convenient for clients to start a custom project anytime
A lower price with fast turnaround
Quality affordable custom antagonist antibodies
The resulting antibody with a guarantee of stability and efficacy

As a well-recognized expert in biomedical fields, Creative Biolabs has been trusted among top scientists for quality biological products and characteristic custom services. Having accomplished a large number of antibody design programs, we’re confident to offer customers the best and comprehensive checkpoint antagonistic antibody or antagonistic autoantibody generation and development services, promoting their specific project a success. For more information, please feel free to contact us.

Reference

Melero, I.; et al. Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res. 2013, 19(5): 997-1008.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: